GB2497502A - Neurodegenerative Disorders - Google Patents
Neurodegenerative Disorders Download PDFInfo
- Publication number
- GB2497502A GB2497502A GB1306866.3A GB201306866A GB2497502A GB 2497502 A GB2497502 A GB 2497502A GB 201306866 A GB201306866 A GB 201306866A GB 2497502 A GB2497502 A GB 2497502A
- Authority
- GB
- United Kingdom
- Prior art keywords
- app
- neurodegenerative disorders
- alzheimer
- proteins
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 3
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 abstract 4
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 abstract 4
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 abstract 4
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 abstract 4
- 208000024827 Alzheimer disease Diseases 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 230000004060 metabolic process Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 101150037123 APOE gene Proteins 0.000 abstract 1
- 102100029470 Apolipoprotein E Human genes 0.000 abstract 1
- 101710095339 Apolipoprotein E Proteins 0.000 abstract 1
- 101100216294 Danio rerio apoeb gene Proteins 0.000 abstract 1
- 238000007423 screening assay Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to neurodegenerative disorders, and in particular, to conditions involving the presence of amyloid precursor protein (APP), such as Alzheimer's disease (AD). The invention relates to novel genes and proteins that are involved in the metabolism of γ-secretase, APP and APP-like proteins, and to methods and screening assays for identifying modulators of APP metabolism. The invention extends to methods for investigating and testing therapies for conditions that are biologically related to apolipoprotein E (apoE), such as neurodegenerative disorders, such as Alzheimer's disease.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1011819.8A GB201011819D0 (en) | 2010-07-14 | 2010-07-14 | Neurodegenerative disorders |
| PCT/GB2011/051291 WO2012007740A1 (en) | 2010-07-14 | 2011-07-11 | Neurodegenerative disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB201306866D0 GB201306866D0 (en) | 2013-05-29 |
| GB2497502A true GB2497502A (en) | 2013-06-12 |
Family
ID=42734915
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB1011819.8A Ceased GB201011819D0 (en) | 2010-07-14 | 2010-07-14 | Neurodegenerative disorders |
| GB1306866.3A Withdrawn GB2497502A (en) | 2010-07-14 | 2011-07-11 | Neurodegenerative Disorders |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB1011819.8A Ceased GB201011819D0 (en) | 2010-07-14 | 2010-07-14 | Neurodegenerative disorders |
Country Status (2)
| Country | Link |
|---|---|
| GB (2) | GB201011819D0 (en) |
| WO (1) | WO2012007740A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106632664B (en) * | 2017-01-12 | 2020-07-10 | 沈阳药科大学 | Apolipoprotein II/I and preparation method, biological function and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003045321A2 (en) * | 2001-11-26 | 2003-06-05 | Exelixis, Inc. | MBMs AS MODIFIERS OF BRANCHING MORPHOGENESIS AND METHODS OF USE |
| WO2003087768A2 (en) * | 2002-04-12 | 2003-10-23 | Mitokor | Targets for therapeutic intervention identified in the mitochondrial proteome |
| WO2004038003A2 (en) * | 2002-10-25 | 2004-05-06 | Five Prime Therapeutics, Inc. | Human polypeptides encoded by polynucleotides and methods of their use |
| WO2008024114A1 (en) * | 2006-08-24 | 2008-02-28 | Genizon Biosciences Inc. | Genemap of the human genes associated with schizophrenia |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7964598B2 (en) | 1995-10-17 | 2011-06-21 | The J. David Gladstone Institutes | ApoE4 domain interaction inhibitors and methods of use thereof |
-
2010
- 2010-07-14 GB GBGB1011819.8A patent/GB201011819D0/en not_active Ceased
-
2011
- 2011-07-11 GB GB1306866.3A patent/GB2497502A/en not_active Withdrawn
- 2011-07-11 WO PCT/GB2011/051291 patent/WO2012007740A1/en active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003045321A2 (en) * | 2001-11-26 | 2003-06-05 | Exelixis, Inc. | MBMs AS MODIFIERS OF BRANCHING MORPHOGENESIS AND METHODS OF USE |
| WO2003087768A2 (en) * | 2002-04-12 | 2003-10-23 | Mitokor | Targets for therapeutic intervention identified in the mitochondrial proteome |
| WO2004038003A2 (en) * | 2002-10-25 | 2004-05-06 | Five Prime Therapeutics, Inc. | Human polypeptides encoded by polynucleotides and methods of their use |
| WO2008024114A1 (en) * | 2006-08-24 | 2008-02-28 | Genizon Biosciences Inc. | Genemap of the human genes associated with schizophrenia |
Non-Patent Citations (5)
| Title |
|---|
| DATABASE Geneseq [Online ]28 March 2003 (2003-03-28), "NOVX related protein SEQ ID No 76.", rEBI accession no.ABJ19355 * |
| DATABASE Geneseq [Online] 1 May 2008 (2008-05-01) ,"Schizophrenia-disorder mapping candidate gene encoded protein SEQ ID 191.", EBI accession no ARK41824 * |
| DATABASE Geneseq [Online] 22 September 2003 (2003-09-22), "Human MBM protein.", EBI accession no. AA030442 * |
| DATABASE Geneseq [Online] 29 July 2004 (2004-07-29), "Novel human protein sequence #437.", EBI accession no ADN99621 * |
| DATABASE Geneseq [Online] 6 May 2004 (2004-05-06), "Human heat mitochondrial protein as a therapeutic target SeqID1742.", EBI accession no. ADJ69936 * |
Also Published As
| Publication number | Publication date |
|---|---|
| GB201011819D0 (en) | 2010-09-01 |
| GB201306866D0 (en) | 2013-05-29 |
| WO2012007740A1 (en) | 2012-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX356800B (en) | Humanized tau antibody. | |
| WO2013181618A3 (en) | Methods to treat alzheimer's disease using apoe inhibitors | |
| WO2013067451A3 (en) | Methods and compositions for diagnosing, prognosing, and treating neurological conditions | |
| MX354662B (en) | Phosphospecific antibodies recognising tau. | |
| MX338421B (en) | Phosphospecific antibodies recognising tau. | |
| MY163521A (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| JO3118B1 (en) | Compositions and methods for antibodies targeting complement protein c5 | |
| MY157173A (en) | Modified humanised anti-interleukin-18 | |
| WO2008076262A3 (en) | Receptor for amyloid beta and uses thereof | |
| MX359570B (en) | Binding proteins inhibiting the vegf-a receptor interaction. | |
| GB201020995D0 (en) | Biological materials and uses thereof | |
| MY159398A (en) | Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide | |
| MY175260A (en) | Prion free nanoparticle compositions and methods of making thereof | |
| MX360403B (en) | Amyloid-beta binding proteins. | |
| WO2011038301A3 (en) | Screening methods | |
| MX2007009807A (en) | Aptamer therapeutics useful in the treatment of complement-related disorders. | |
| NZ591613A (en) | Polymorphic marker rs965513 for risk assessment of thyroid cancer | |
| MX346500B (en) | Methods and compositions for neural disease immunotherapy. | |
| MX341178B (en) | Methods for determining gene-nutrient interactions. | |
| WO2010004591A3 (en) | Genetic variants for breast cancer risk assessment | |
| MX2009008410A (en) | Binding members for ige molecules. | |
| WO2011106541A3 (en) | Diagnostic methods involving loss of heterozygosity | |
| IN2015MN00027A (en) | ||
| PH12014501200A1 (en) | Bacteriophage gene 3 protein compositions and use as amyloid binding agents | |
| GB2496801A (en) | A method of treating alzheimer's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |